TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11783029

Group type: EXPERIMENTAL
Intervention: Carboplatin solution (injection group)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Carboplatin powder (control group)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both groups (study and control)
Number of subjects: 121
Study: 9196144

Group type: EXPERIMENTAL
Intervention: TAM plus CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2 every 21 days for eight cycles)
Number of subjects: 705
Study: 1604252

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 47
Study: 3886325

Group type: EXPERIMENTAL
Intervention: Skin stapling technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 50
Study: 30696755

Group type: EXPERIMENTAL
Intervention: 6-Minute Stationary Walk Test associated with Virtual Reality (STVR-6)
Number of subjects: 50
Study: 29126686

Group type: EXPERIMENTAL
Intervention: RBC transfusion threshold of Hb 80 g/L
Number of subjects: 80

Group type: COMPARATOR
Intervention: RBC transfusion threshold of Hb 100 g/L
Number of subjects: 80
Study: 24933196

Group type: EXPERIMENTAL
Intervention: Admiral oxygenator (Group 1, G1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional CPB (Group 2, G2)
Number of subjects: 30
Study: 24606873

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy for Anorexia Nervosa (CBT-AN)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management (SSCM)
Number of subjects: 63
Study: 22768456

Group type: EXPERIMENTAL
Intervention: Assertiveness training (5 sessions)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 89
Study: 21298125

Group type: EXPERIMENTAL
Intervention: Gestational hypertension group (n=17)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pregestational hypertension group (n=14)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (n=17)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hypertensive women with preeclampsia
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hypertensive women without preeclampsia
Number of subjects: 48
Study: 18008221

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (types 6, 11, 16, and 18)
Number of subjects: 17622
Study: 16153520

Group type: EXPERIMENTAL
Intervention: Transthoracic Doppler echocardiography measuring diastolic‐to‐systolic blood flow velocity ratio (DSVR)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Thallium 201 single photon emission computed tomography
Number of subjects: 95
Study: 11550961

Group type: EXPERIMENTAL
Intervention: 50 mg doxycycline twice a day
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 9013904

Group type: EXPERIMENTAL
Intervention: Knitted Dacron polyester graft impregnated with collagen
Number of subjects: 244

Group type: COMPARATOR
Intervention: Thin-wall expanded reinforced PTFE graft
Number of subjects: 244
Study: 7933707

Group type: EXPERIMENTAL
Intervention: Sodium valproate (200 or 400 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 18
Study: 3284491

Group type: EXPERIMENTAL
Intervention: Glucose-containing priming solutions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonglucose primes
Number of subjects: 50
Study: 2012295

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 20
Study: 1106289

Group type: EXPERIMENTAL
Intervention: Treatment by clinic nutritionist and physician with the National Heart and Lung Institute's type IV diet for 6 weeks, then diet plus clofibrate for 18 weeks.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Same treatment by private physician.
Number of subjects: 150

Group type: COMPARATOR
Intervention: No intervention for 24 weeks, subjects advised of abnormality.
Number of subjects: 150
Study: 31900135

Group type: EXPERIMENTAL
Intervention: Virtual reality teaching group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional teaching group
Number of subjects: 30
Study: 30126754

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography with incision and drainage
Number of subjects: 125

Group type: COMPARATOR
Intervention: Physical examination alone with incision and drainage
Number of subjects: 125
Study: 28917226

Group type: EXPERIMENTAL
Intervention: Average daily energy intake <50% of requirement (Group A)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Average daily energy intake >=50% of requirement (Group B)
Number of subjects: 72
Study: 25776489

Group type: EXPERIMENTAL
Intervention: Needle administration of bupivacaine (0.5%, 15 mL, 0.3 mL/s)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Catheter administration of bupivacaine (0.5%, 15 mL, 0.3 mL/s)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Catheter administration of bupivacaine in female patients
Number of subjects: 23
Study: 24224403

Group type: EXPERIMENTAL
Intervention: Fluorometholone nasal drops with positional and feeding changes
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Positional and feeding changes
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 21785918

Group type: EXPERIMENTAL
Intervention: Short pouch double tract (SPDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long pouch double tract (LPDT)
Number of subjects: 0
Study: 19954717

Group type: EXPERIMENTAL
Intervention: Thrombo (EIPICO, Egypt) 75 mg tablets
Number of subjects: 32

Group type: COMPARATOR
Intervention: Plavix (Sanofi Pharma/Bristol‐Myers Squibb, Paris, France) 75 mg tablets
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Thrombo (EIPICO, Egypt) 75 mg tablets (clopidogrel carboxylic acid metabolite)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Plavix (Sanofi Pharma/Bristol‐Myers Squibb, Paris, France) 75 mg tablets (clopidogrel carboxylic acid metabolite)
Number of subjects: 32
Study: 16765700

Group type: EXPERIMENTAL
Intervention: timolol‐dorzolamide combination
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: timolol‐pilocarpine combination
Number of subjects: 16
Study: 15257114

Group type: EXPERIMENTAL
Intervention: Natural beta-carotene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11312403

Group type: EXPERIMENTAL
Intervention: Single breath transfer factor (TCO)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Transfer coefficient (KCO)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard protocol measurements
Number of subjects: 68
Study: 9273873

Group type: EXPERIMENTAL
Intervention: Succimer (meso‐2, 3‐dimercaptosuccinic acid) at a daily dose of 30 mg/kg for five days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7936800

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler sonography (TCD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: MRA
Number of subjects: 0
Study: 3222686

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: (+/-)-nicardipine (20 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg) and (+/-)-nicardipine (20 mg)
Number of subjects: 80
Study: 29079414

Group type: EXPERIMENTAL
Intervention: OCT guidance during pPCI
Number of subjects: 201

Group type: COMPARATOR
Intervention: Angio-guided pPCI
Number of subjects: 201
Study: 28874646

Group type: EXPERIMENTAL
Intervention: Triangular flap
Number of subjects: 50

Group type: COMPARATOR
Intervention: Envelope flap
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 26083696

Group type: EXPERIMENTAL
Intervention: Guided skiing intervention (12 weeks, average of 25.5 days of skiing)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no skiing intervention)
Number of subjects: 31
Study: 22111872

Group type: COMPARATOR
Intervention: Conventional complete dentures (CCDs)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Implant-retained overdentures (IODs)
Number of subjects: 122
Study: 21473839

Group type: EXPERIMENTAL
Intervention: Fluoride gel (Elmex gel)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diode laser + fluoride gel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diode laser before fluoride application
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 20
Study: 18408986

Group type: EXPERIMENTAL
Intervention: CO(2) laser irradiation (1 W of power in de‐focused continuous mode)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (non-thermal gel)
Number of subjects: 15
Study: 16684124

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Withdrawal of imatinib
Number of subjects: 84
Study: 15575343

Group type: EXPERIMENTAL
Intervention: Orlistat (360 mg/d)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sibutramine (10 mg/d)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both Orlistat and Sibutramine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sibutramine
Number of subjects: 144
Study: 11573635

Group type: EXPERIMENTAL
Intervention: Selective spinal anaesthesia (SSA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol general anaesthesia (GA)
Number of subjects: 40
Study: 9782075

Group type: EXPERIMENTAL
Intervention: 135 mg m-2 paclitaxel administered by 3-hour infusion
Number of subjects: 13
Study: 7929727

Group type: EXPERIMENTAL
Intervention: Out-patient management with early, ultrasound-guided trans-abdominal paracentesis, intravenous hydration, fluid removal of 1-3 liters over 2-3 hours.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conservative management with hospitalization, intravenous hydration, and supportive therapy.
Number of subjects: 18
Study: 3281014

Group type: EXPERIMENTAL
Intervention: Early discharge (day 3)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Conventional discharge (days 7 to 10)
Number of subjects: 179
Study: 31580702

Group type: EXPERIMENTAL
Intervention: OSA Knowledge and Attitudes (OSAKA) questionnaire
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: OSA Knowledge and Attitudes in Children (OSAKA-KIDS) questionnaire
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Confidence in OSA diagnosis and management
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prescribing practices
Number of subjects: 120
Study: 30982686

Group type: EXPERIMENTAL
Intervention: FLOT (fluorouracil plus leucovorin, oxaliplatin, and docetaxel)
Number of subjects: 716

Group type: COMPARATOR
Intervention: ECF/ECX (epirubicin and cisplatin with fluorouracil or capecitabine)
Number of subjects: 716
Study: 28851373

Group type: EXPERIMENTAL
Intervention: Pragmatic lifestyle modification programme (P-LSM)
Number of subjects: 3539

Group type: COMPARATOR
Intervention: Control lifestyle modification (C-LSM)
Number of subjects: 3539
Study: 25744288

Group type: EXPERIMENTAL
Intervention: Take Care intervention
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 23425051

Group type: EXPERIMENTAL
Intervention: Local steroid injection and balloon dilatation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Steroid application and balloon dilatation
Number of subjects: 43
Study: 21729834

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Cypher® stent (SES)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Zotarolimus-eluting Endeavor® stent (ZES)
Number of subjects: 127
Study: 18832295

Group type: EXPERIMENTAL
Intervention: Vildagliptin 25 to 200 mg qd
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vildagliptin 200 mg qd
Number of subjects: 60
Study: 16384760

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 mg 5 times daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 15631798

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g i.v. before and after surgery)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Cefoperazone plus sulbactam (sulperazon) (2 g i.v. before and after surgery)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 190

Group type: COMPARATOR
Intervention: Cefoperazone plus sulbactam (sulperazon)
Number of subjects: 190
Study: 11052511

Group type: EXPERIMENTAL
Intervention: 2 percent diltiazem gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.1 percent bethanechol gel
Number of subjects: 30
Study: 9353681

Group type: EXPERIMENTAL
Intervention: Nutrition intervention focused on low-fat eating pattern changes among 134 EFNEP participants.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Nutrition education materials provided to 70 comparison participants (Control group).
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Nutrition intervention among 134 EFNEP participants.
Number of subjects: 204
Study: 1524960

Group type: EXPERIMENTAL
Intervention: pH-feedback controlled infusion of ranitidine (maximum dose 800 mg 24 h-1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: fixed-dose infusion of ranitidine (0.25 mg kg-1 h-1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: pH-feedback controlled infusion of ranitidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: fixed-rate infusion of ranitidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: fixed-dose infusion of ranitidine
Number of subjects: 10
Study: 3890864

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30281086

Group type: EXPERIMENTAL
Intervention: CBT2go (cognitive behavioral therapy combined with automated thought challenging/adaptive behavior)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Self-Monitoring (single-session illness psychoeducation with self-monitoring of symptoms)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: CBT2go
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Self-Monitoring (SM)
Number of subjects: 255
Study: 29979388

Group type: EXPERIMENTAL
Intervention: Comprehensive blood-saving strategy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Traditional routine CPB
Number of subjects: 86
Study: 25301224

Group type: EXPERIMENTAL
Intervention: Accelerometer-based assessment of moderate-to-vigorous-intensity physical activity (MVPA)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Self-reported assessment of moderate-to-vigorous-intensity physical activity (MVPA)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Accelerometer-based assessment of sedentary time
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Self-reported assessment of sedentary time
Number of subjects: 176
Study: 23646468

Group type: EXPERIMENTAL
Intervention: Rhubarb powder (5-10 g dissolved in 40 mL warm water, administered nasally 2-3 times daily for 10 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (routine Western medical treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rhubarb powder
Number of subjects: 40
Study: 20932581

Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (AGV; model FP7)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Baerveldt glaucoma implant (BGI; model 101-350)
Number of subjects: 276
Study: 19241772

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.4% (Acular LS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Refresh Tears (placebo)
Number of subjects: 30
Study: 17520467

Group type: EXPERIMENTAL
Intervention: Azithromycin, 500 mg weekly for 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: E-test for in vitro susceptibility
Number of subjects: 24
Study: 15074089

Group type: EXPERIMENTAL
Intervention: Jingling oral liquid (JLOL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular injection of human chorionic gonadotropine (hCG)
Number of subjects: 60
Study: 11176258

Group type: EXPERIMENTAL
Intervention: Iomeprol
Number of subjects: 600

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 600

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 600

Group type: COMPARATOR
Intervention: Iotrolan
Number of subjects: 600
Study: 9720158

Group type: EXPERIMENTAL
Intervention: Permanent ICA clipping (performed in 6 cases, 1.3% of all surgeries)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Intraoperative bleeding from aneurysms of the ophthalmic segment of ICA (19 cases)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Permanent ICA clipping (in cases of intraoperative bleeding)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Permanent ICA clipping (6 patients)
Number of subjects: 470
Study: 9688036

Group type: COMPARATOR
Intervention: 10 mg triamcinolone acetonide
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide
Number of subjects: 57
Study: 1807994

Group type: EXPERIMENTAL
Intervention: Modified Rinn positioner
Number of subjects: 211

Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 211

Group type: COMPARATOR
Intervention: Rinn positioner
Number of subjects: 211

Group type: COMPARATOR
Intervention: HPL device
Number of subjects: 211
Study: 6336794

Group type: EXPERIMENTAL
Intervention: Stress management training and dietary changes
Number of subjects: 23
Study: 30446275

Group type: EXPERIMENTAL
Intervention: Non-pegylated liposomal doxorubicin (NPLD) + carboplatin (AUC 5 mg/min.mL, dose escalation from 40 to 50 mg/m2)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Non-pegylated liposomal doxorubicin (NPLD) + carboplatin
Number of subjects: 87
Study: 29558756

Group type: EXPERIMENTAL
Intervention: Network consulting room management (video, voice, text, electronic prescriptions)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Traditional management
Number of subjects: 240
Study: 26411859

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR) using a polyglycolide membrane
Number of subjects: 18

Group type: COMPARATOR
Intervention: Access Flap (AF) surgery
Number of subjects: 18
Study: 24078107

Group type: EXPERIMENTAL
Intervention: Placebo/WL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naltrexone/WL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo/Neutral
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WL (vs Neutral)
Number of subjects: 0
Study: 22459773

Group type: EXPERIMENTAL
Intervention: Standard management pathway based on evidence‐based cough algorithm
Number of subjects: 346
Study: 19995131

Group type: EXPERIMENTAL
Intervention: Milk (114 g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tempeh (206 g)
Number of subjects: 20
Study: 17621379

Group type: EXPERIMENTAL
Intervention: Trained CMHN providing psychosocial intervention (PSI)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual practice CMHN
Number of subjects: 113
Study: 15966887

Group type: EXPERIMENTAL
Intervention: Crest Gum Care
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Mentadent P
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Crest Gum Care and Mentadent P
Number of subjects: 110
Study: 12030915

Group type: EXPERIMENTAL
Intervention: 2.5% testosterone gel preparation
Number of subjects: 28
Study: 9793615

Group type: EXPERIMENTAL
Intervention: 200 mg naftidrofuryl (Praxilene)
Number of subjects: 30
Study: 8293835

Group type: EXPERIMENTAL
Intervention: Bioadhesive vaginal moisturizer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Local estrogen therapy
Number of subjects: 30
Study: 3276526

Group type: EXPERIMENTAL
Intervention: High-dose surfactant (120 mg/kg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low-dose surfactant (60 mg/kg)
Number of subjects: 46
Study: 1103113

Group type: EXPERIMENTAL
Intervention: Feprazone 450 mg daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Indomethacin 75 mg daily
Number of subjects: 14
Study: 31364144

Group type: EXPERIMENTAL
Intervention: Oral supplements (OS) with immune-stimulating molecules (Sambucus nigra, Zinc, Tyndallized Lactobacillus acidophilus (H122), Arabinogalactans, vitamin D, vitamin E, vitamin C)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Oral supplements (OS) with immune-stimulating molecules (Group 2)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Oral supplements (OS) with immune-stimulating molecules (Group 2 and 3)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard treatment for rhinitis and OME (Control group)
Number of subjects: 198
Study: 28715908

Group type: EXPERIMENTAL
Intervention: Prolonged exposure treatment (N=36)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Single-pulse transcranial magnetic stimulation (TMS) concurrent with fMRI (N=17 subset of prolonged exposure group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Waiting list condition (N=30)
Number of subjects: 66
Study: 24728329

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX) at doses 10, 15, 20, and 25 mg weekly
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Subcutaneous methotrexate (SC MTX) administered via auto-injector (MTXAI) at doses 10, 15, 20, and 25 mg weekly
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Subcutaneous methotrexate (SC MTX)
Number of subjects: 47
Study: 24337328

Group type: EXPERIMENTAL
Intervention: Integrated Emotion-Oriented Care (IEOC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 16
Study: 20538128

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (LLT)
Number of subjects: 913
Study: 18580406

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise program (walking 10,000 steps, three times a week)
Number of subjects: 34
Study: 16884344

Group type: EXPERIMENTAL
Intervention: Aromatherapy (n = 25) - topical application of lavender, clary sage, and rose in almond oil
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (n = 20) - almond oil only
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (n = 22) - no treatment
Number of subjects: 67
Study: 14626377

Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone therapy (HT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term hormone therapy (HT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temporary interruption of hormone therapy (HT) before mammography
Number of subjects: 0
Study: 10805048

Group type: EXPERIMENTAL
Intervention: Home BP measurement device (OMRON)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Losartan treatment
Number of subjects: 622